These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
301 related articles for article (PubMed ID: 21625441)
1. Screen for IDH1, IDH2, IDH3, D2HGDH and L2HGDH mutations in glioblastoma. Krell D; Assoku M; Galloway M; Mulholland P; Tomlinson I; Bardella C PLoS One; 2011; 6(5):e19868. PubMed ID: 21625441 [TBL] [Abstract][Full Text] [Related]
2. IDH1 and IDH2 have critical roles in 2-hydroxyglutarate production in D-2-hydroxyglutarate dehydrogenase depleted cells. Matsunaga H; Futakuchi-Tsuchida A; Takahashi M; Ishikawa T; Tsuji M; Ando O Biochem Biophys Res Commun; 2012 Jul; 423(3):553-6. PubMed ID: 22683334 [TBL] [Abstract][Full Text] [Related]
3. Mutational analysis of D2HGDH and L2HGDH in brain tumours without IDH1 or IDH2 mutations. Brehmer S; Pusch S; Schmieder K; von Deimling A; Hartmann C Neuropathol Appl Neurobiol; 2011 Apr; 37(3):330-2. PubMed ID: 20727073 [No Abstract] [Full Text] [Related]
5. IDH1 and IDH2 mutations in gliomas. Yan H; Parsons DW; Jin G; McLendon R; Rasheed BA; Yuan W; Kos I; Batinic-Haberle I; Jones S; Riggins GJ; Friedman H; Friedman A; Reardon D; Herndon J; Kinzler KW; Velculescu VE; Vogelstein B; Bigner DD N Engl J Med; 2009 Feb; 360(8):765-73. PubMed ID: 19228619 [TBL] [Abstract][Full Text] [Related]
6. 2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations. Jin G; Reitman ZJ; Spasojevic I; Batinic-Haberle I; Yang J; Schmidt-Kittler O; Bigner DD; Yan H PLoS One; 2011 Feb; 6(2):e16812. PubMed ID: 21326614 [TBL] [Abstract][Full Text] [Related]
7. CRISPR Editing of Mutant IDH1 R132H Induces a CpG Methylation-Low State in Patient-Derived Glioma Models of G-CIMP. Moure CJ; Diplas BH; Chen LH; Yang R; Pirozzi CJ; Wang Z; Spasojevic I; Waitkus MS; He Y; Yan H Mol Cancer Res; 2019 Oct; 17(10):2042-2050. PubMed ID: 31292202 [TBL] [Abstract][Full Text] [Related]
8. The potential for isocitrate dehydrogenase mutations to produce 2-hydroxyglutarate depends on allele specificity and subcellular compartmentalization. Ward PS; Lu C; Cross JR; Abdel-Wahab O; Levine RL; Schwartz GK; Thompson CB J Biol Chem; 2013 Feb; 288(6):3804-15. PubMed ID: 23264629 [TBL] [Abstract][Full Text] [Related]
9. D2HGDH regulates alpha-ketoglutarate levels and dioxygenase function by modulating IDH2. Lin AP; Abbas S; Kim SW; Ortega M; Bouamar H; Escobedo Y; Varadarajan P; Qin Y; Sudderth J; Schulz E; Deutsch A; Mohan S; Ulz P; Neumeister P; Rakheja D; Gao X; Hinck A; Weintraub ST; DeBerardinis RJ; Sill H; Dahia PL; Aguiar RC Nat Commun; 2015 Jul; 6():7768. PubMed ID: 26178471 [TBL] [Abstract][Full Text] [Related]
10. Biological Significance of Mutant Isocitrate Dehydrogenase 1 and 2 in Gliomagenesis. Ohba S; Hirose Y Neurol Med Chir (Tokyo); 2016; 56(4):170-9. PubMed ID: 26960449 [TBL] [Abstract][Full Text] [Related]
11. Isocitrate dehydrogenase gene mutations and 2-hydroxyglutarate accumulation in esophageal squamous cell carcinoma. Miyake K; Baba Y; Ishimoto T; Hiyoshi Y; Iwatsuki M; Miyamoto Y; Yoshida N; Watanabe M; Ogata Y; Nagayama M; Silsirivanit A; Kobayashi D; Araki N; Baba H Med Oncol; 2018 Nov; 36(1):11. PubMed ID: 30506321 [TBL] [Abstract][Full Text] [Related]
12. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Dang L; White DW; Gross S; Bennett BD; Bittinger MA; Driggers EM; Fantin VR; Jang HG; Jin S; Keenan MC; Marks KM; Prins RM; Ward PS; Yen KE; Liau LM; Rabinowitz JD; Cantley LC; Thompson CB; Vander Heiden MG; Su SM Nature; 2009 Dec; 462(7274):739-44. PubMed ID: 19935646 [TBL] [Abstract][Full Text] [Related]
13. IDH2 mutation in gliomas including novel mutation. Koh J; Cho H; Kim H; Kim SI; Yun S; Park CK; Lee SH; Choi SH; Park SH Neuropathology; 2015 Jun; 35(3):236-44. PubMed ID: 25495392 [TBL] [Abstract][Full Text] [Related]
14. Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma? Kloosterhof NK; Bralten LB; Dubbink HJ; French PJ; van den Bent MJ Lancet Oncol; 2011 Jan; 12(1):83-91. PubMed ID: 20615753 [TBL] [Abstract][Full Text] [Related]
15. IDH1 and IDH2 mutations, immunohistochemistry and associations in a series of brain tumors. Mellai M; Piazzi A; Caldera V; Monzeglio O; Cassoni P; Valente G; Schiffer D J Neurooncol; 2011 Nov; 105(2):345-57. PubMed ID: 21643842 [TBL] [Abstract][Full Text] [Related]
16. Isocitrate dehydrogenase mutation as a therapeutic target in gliomas. Han CH; Batchelor TT Chin Clin Oncol; 2017 Jun; 6(3):33. PubMed ID: 28705010 [TBL] [Abstract][Full Text] [Related]
17. IDH1/IDH2 but not TP53 mutations predict prognosis in Bulgarian glioblastoma patients. Stancheva G; Goranova T; Laleva M; Kamenova M; Mitkova A; Velinov N; Poptodorov G; Mitev V; Kaneva R; Gabrovsky N Biomed Res Int; 2014; 2014():654727. PubMed ID: 24868540 [TBL] [Abstract][Full Text] [Related]
18. Isocitrate dehydrogenase mutations in gliomas. Waitkus MS; Diplas BH; Yan H Neuro Oncol; 2016 Jan; 18(1):16-26. PubMed ID: 26188014 [TBL] [Abstract][Full Text] [Related]
19. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. Amary MF; Bacsi K; Maggiani F; Damato S; Halai D; Berisha F; Pollock R; O'Donnell P; Grigoriadis A; Diss T; Eskandarpour M; Presneau N; Hogendoorn PC; Futreal A; Tirabosco R; Flanagan AM J Pathol; 2011 Jul; 224(3):334-43. PubMed ID: 21598255 [TBL] [Abstract][Full Text] [Related]
20. Isocitrate dehydrogenase mutations: a challenge to traditional views on the genesis and malignant progression of gliomas. Weller M; Wick W; von Deimling A Glia; 2011 Aug; 59(8):1200-4. PubMed ID: 21294161 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]